Immunotargeting & Immunotheragnostics.....
..... is here
Our proprietary technology targets and specifically sensitizes cancer cells in such a way that they show enhanced response (cell death) to radiation
Targeted payload delivery
Be it carrying a therapeutic payload or an imaging agent to monitor response or a combination of both – we are developing specific targeting moieties tethered to liposomes in formulation that enables targeted delivery to cancer cells.
Our pipeline of antibodies and single chain variable fragments (scFv’s) have demonstrated cytotoxic effects against cancer cells, specifically towards Non-Small Cell
Dennis Hallahan, MD.
Dennis Hallahan, MD has started 5 biotechnology companies, 2 of them publicly traded (Genvec, Inc.& Cumberland Emerging Technologies). Dr. Hallahan has established several service companies. He has experience of launching and exiting from companies that he has founded. Dr. Hallahan has developed several drugs that have entered Phase I through Phase III clinical trials.
Stephanie Hallahan, MBA.
President & CEO
Stephanie Hallahan, MBA as our President and CEO, leading the company. She has been in this position since 2013 and has had direct oversight of phase I STTR and SBIR grants and phase II SBIR grants. She had a successful combined 20 years of career managing research teams, IP, and licensing. This career included management of millions in budgets and negotiations of hundreds of contracts and agreements. Stephanie is seasoned in discussing investment opportunities with potential scientific and financial partners. In addition to being an author on a number of scientific papers, Stephanie trained at the Center for Emerging Technology in the Bio-Entrepreneur Development Program.
Sapna Deore, Ph.D.
Sapna Deore, Ph.D obtained her undergraduate degree in Biotechnology from Govt. Institute of Science, Aurangabad, India. She received Research Fellowship funded by the University grant commission (UGC), for pursuing her Ph.D. in Biotechnology from National Centre for Cell Sciences, Pune, India. Her doctoral work was in the field of adaptive immunity pertaining to malaria infection. During her work on identifying peptides that can interfere with the invasion of the malarial parasite in the host erythrocyte, she developed a strong interest in the area of drug development. At Medgyde, with her experience and passion for drug development she will carry out R&D activities on our novel cancer drug pipeline.
Sriram Devanathan, Ph.D.
Sriram Devanathan, Ph.D, leads research activities at MGS by overseeing and coordinating with other partners. He has a strong molecular and biomarker discovery expertise. He has served as Life Science consultant conducting multiple technology and market evaluations, Due Diligence, and Business plan evaluations and is a graduate of Square One program from Centre for Emerging Technologies. With this unique skill set, he leads MGS activities to demonstrate preclinical proof of concept and clinical trial of cancer theragnostic agents.
Dennis Hallahan, MD
Stephanie Hallahan, MBA
Michael Kinch, Ph.D.
Michael S. Kinch, PhD, is the associate vice chancellor and director of the Center for Research Innovation in Business at Washington University in Saint Louis. Michael’s scientific expertise includes pre-clinical drug development for cancer, immunological and infectious diseases with small molecules, monoclonal antibodies and other biologics. Michael was a professor at Purdue University, studying monoclonal antibody targeting of cancer and went on to lead oncology at MedImmune Inc., and was Chief Scientific Officer at Functional Genetics Inc and Managing Director of the Yale Center for Molecular Discovery.